The journal of allergy and clinical immunology. Global最新文献

{"title":"Indoor allergens and endotoxins in relation to cockroach infestations in low-income urban homes","authors":"Madhavi L. Kakumanu MS, PhD ,&nbsp;Zachary C. DeVries MS, PhD ,&nbsp;Richard G. Santangelo BS ,&nbsp;Jeffrey Siegel MS, PhD ,&nbsp;Coby Schal PhD","doi":"10.1016/j.jacig.2025.100571","DOIUrl":"10.1016/j.jacig.2025.100571","url":null,"abstract":"<div><h3>Background</h3><div>Cockroach allergens are well recognized as important risk factors in the development and prevalence of allergic rhinitis and asthma in children, especially in low-income urban households. The German cockroach gut hosts a diverse community of highly abundant microbes, including gram-negative bacteria that shed large amounts of endotoxins in cockroach feces.</div></div><div><h3>Objective</h3><div>We sought to delineate the causal relationship between the presence of cockroaches in homes and levels of household endotoxins.</div></div><div><h3>Methods</h3><div>In laboratory assays, we measured the amount of endotoxin produced by cockroaches. In-home monitoring estimated the size of the cockroach population in each home and quantified cockroach allergen Bla g 2 and endotoxin levels in household dust and on heating, ventilating, and air-conditioning (HVAC) filters. An environmental intervention was implemented in a subset of the infested homes to eliminate cockroaches. Bla g 2 and endotoxin levels were quantified for 6 months after the intervention.</div></div><div><h3>Results</h3><div>Large amounts of endotoxin are excreted by female (2900 endotoxin units [EU]/mg feces) and male (1400 EU/mg) cockroaches. At baseline, household dust and HVAC filters in infested homes had significantly higher levels of allergen (Bla g 2) and endotoxin than uninfested homes. Environmental intervention resulted in significant declines in cockroaches as well as allergen and endotoxin levels. In contrast, cockroach numbers and allergen and endotoxin concentrations remained high in infested-control homes.</div></div><div><h3>Conclusions</h3><div>Cockroaches are a significant source of both endotoxins and potent allergens, potentially resulting in coexposure of asthmatic children to both.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"5 1","pages":"Article 100571"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145365663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vitro potency and pharmacokinetics of APG777, a novel anti–IL-13 mAb","authors":"Eric Zhu PhD ,&nbsp;Holly Prentice PhD ,&nbsp;Jason Oh PhD ,&nbsp;Hussam Shaheen PhD ,&nbsp;Namita A. Gandhi PhD ,&nbsp;Grant Wickman PhD ,&nbsp;Rebecca Dabora PhD ,&nbsp;Carl L. Dambkowski MD ,&nbsp;Lukas Dillinger PhD","doi":"10.1016/j.jacig.2025.100545","DOIUrl":"10.1016/j.jacig.2025.100545","url":null,"abstract":"<div><h3>Background</h3><div>IL-13 plays a key role in the induction and perpetuation of type 2 immune responses associated with the development of atopic dermatitis and other chronic inflammatory diseases. mAbs targeting IL-13 have demonstrated efficacy in IL-13–driven diseases; however, current therapeutics require dosing every 2 to 4 weeks, resulting in significant injection burden for patients. APG777 is a humanized, IgG1 IL-13–targeting mAb that has been engineered to have an optimized pharmacokinetic profile, allowing for less frequent dosing.</div></div><div><h3>Objective</h3><div>We sought to investigate the <em>in vitro</em> potency and <em>in vivo</em> pharmacokinetics of APG777.</div></div><div><h3>Methods</h3><div>The affinity of APG777 was characterized using surface plasmon resonance; the half-maximal inhibitory concentration (IC₅₀) of APG777 was determined in various <em>in vitro</em> assays measuring inhibition of IL-13 signaling via signal transducer and activator of transcription 6 phosphorylation and chemokine release in relevant cell lines. Pharmacokinetics of APG777 were evaluated in nonhuman primates following a single intravenous or subcutaneous infusion. All studies included lebrikizumab produced based on the publicly available sequence as key comparator.</div></div><div><h3>Results</h3><div>APG777 demonstrated a similar <em>in vitro</em> potency across numerous assays compared with lebrikizumab and a 2-fold longer serum half-life following subcutaneous injection in nonhuman primates.</div></div><div><h3>Conclusions</h3><div>These data provide evidence in support of the clinical potential of APG777 in diseases where IL-13 signaling is a main driver of the inflammatory response. The prolonged half-life of APG777 may enable less frequent dosing compared with current treatments, which could reduce injection burden and increase compliance. APG777 is currently being investigated in a phase 2 randomized, controlled trial in patients with atopic dermatitis.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"4 4","pages":"Article 100545"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144916647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying therapeutic targets for allergic asthma through atopic dermatitis–associated genetic mechanisms","authors":"Yuping Pu MSc ,&nbsp;Jundong Liu PhD ,&nbsp;Adam N. Bennett PhD ,&nbsp;Kei Hang Katie Chan PhD","doi":"10.1016/j.jacig.2025.100568","DOIUrl":"10.1016/j.jacig.2025.100568","url":null,"abstract":"<div><h3>Background</h3><div>Allergic asthma (AA) is a chronic inflammatory disease with limited effective treatments, often co-occurring with atopic dermatitis (AD). Epidemiologic studies have shown a strong association between AD and AA, but their causal relationship remains unclear.</div></div><div><h3>Objectives</h3><div>This study aimed to identify novel therapeutic targets and candidate drugs for AA.</div></div><div><h3>Methods</h3><div>We performed Mendelian (MR) analysis to evaluate the causal relationship between AD and AA. To identify potential therapeutic targets, we integrated drug-target MR, colocalization, functional enrichment, protein–protein interaction, and gene expression analyses. Drug candidates were prioritized using the Drug–Gene Interaction Database (DGIdb; <span><span>dgidb.org</span><svg><path></path></svg></span>) and the Comparative Toxicogenomics Database (CTD; <span><span>ctdbase.org</span><svg><path></path></svg></span>).</div></div><div><h3>Results</h3><div>MR analysis confirmed that AD significantly increases the risk of AA (odds ratio = 1.64, <em>P</em> &lt; .001). Integrating drug-target MR and colocalization analysis, we identified Janus kinase 2 <em>(JAK2)</em> as a potential causal gene (posterior probability [PP.H4] = 0.95), supported by functional enrichment, protein–protein interaction, and gene expression analyses. Drug screening via DGIdb and CTD prioritized hydroxyurea as the top candidate (composite score = 0.85), although its efficacy in AA remains to be validated.</div></div><div><h3>Conclusions</h3><div>We provide the first genomic evidence for a causal link between AD and AA. These findings highlight <em>JAK2</em> as a potential therapeutic target and hydroxyurea as a candidate for clinical validation, paving the way for future research into shared immunogenetic mechanisms in allergic diseases.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"4 4","pages":"Article 100568"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145324555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allergy and dermatology US treatment guidelines review for adults with atopic dermatitis","authors":"Constance Bindernagel DO, MBA ,&nbsp;Richard Bindernagel DO, MBA ,&nbsp;Baylee Fulford BS ,&nbsp;Henry Tremain BA ,&nbsp;Monica Hajirawala MD ,&nbsp;Richard Miller DO ,&nbsp;Dennis Ledford MD","doi":"10.1016/j.jacig.2025.100569","DOIUrl":"10.1016/j.jacig.2025.100569","url":null,"abstract":"<div><h3>Background</h3><div>Atopic dermatitis (AD) is a chronic, inflammatory condition that affects patients of all ages. Dermatologists and allergists often treat these patients, with each group of specialists following distinct sets of guidelines. Therefore, patients may receive different management depending on the specialist whom they consult.</div></div><div><h3>Objective</h3><div>The goal of this article is to identify similarities and differences in the treatment of adults with AD using the most recent management guidelines in the United States put forth by the American Academy of Dermatology (AAD) and the American Academy of Allergy, Asthma &amp; Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters.</div></div><div><h3>Methods</h3><div>The management guidelines for adults with AD from the American Academy of Dermatology and the American Academy of Allergy, Asthma &amp; Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters were reviewed to highlight similarities and differences.</div></div><div><h3>Results</h3><div>We identified key similarities in the use of newer biologic agents, including dupilumab and tralokinumab. There are differences between the recommendations for topical phosphodiesterase-4 inhibitors, including crisaborole, and both topical and systemic Janus kinase inhibitors, including ruxolitinib, upadacitinib, abrocitinib, and baricitinib.</div></div><div><h3>Conclusion</h3><div>This article highlights the fact that although the updated management guidelines for adults with AD in dermatology and allergy align on certain recommendations, notable differences that could influence clinical decision making remain. Despite both sets of guidelines being evidence-based, variations in recommendations arise when factoring in patient preferences, perspectives, and risk aversion. As newer treatments become available for patients with AD, it will be important to monitor the evolving concordance or discordance of these guidelines given their direct impact on patient care.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"4 4","pages":"Article 100569"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145264784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical recommendations for diagnosis and management of Mendelian susceptibility to mycobacterial disease in resource-limited settings","authors":"Helena Cornelissen MD ,&nbsp;Brigitte Glanzmann PhD ,&nbsp;Ansia van Coller PhD ,&nbsp;Richard Glashoff PhD ,&nbsp;Rayan Goda MD ,&nbsp;Omaima Abdelmajeed MD ,&nbsp;Nahla Erwa MD ,&nbsp;Monika Esser MD","doi":"10.1016/j.jacig.2025.100540","DOIUrl":"10.1016/j.jacig.2025.100540","url":null,"abstract":"<div><h3>Background</h3><div>Mendelian susceptibility to mycobacterial disease (MSMD) is a rare inborn error of immunity caused by defects in IL-12 or IFN-γ signaling pathways, essential for intracellular pathogen control. While classically linked to nontuberculous mycobacteria, MSMD also predisposes to bacterial, fungal, and viral infections.</div></div><div><h3>Objective</h3><div>We sought to provide a practical framework for diagnosing and managing MSMD in African settings. Recommendations integrate clinical evaluation, baseline immunologic testing, and molecular diagnostics.</div></div><div><h3>Methods</h3><div>A review of clinical presentation, diagnostic strategies, and therapeutic approaches was conducted, emphasizing applicability in resource-limited environments.</div></div><div><h3>Results</h3><div>MSMD presents across a wide clinical spectrum that includes severe disseminated early-onset infections and localized later-onset disease. While classically characterized by increased susceptibility to nontuberculous mycobacteria, MSMD also predisposes to bacterial, fungal, and viral infections. Standard immunologic screening often yields unremarkable findings, necessitating a tiered diagnostic approach that includes molecular testing for confirmation. Long-term antimicrobial therapy remains the cornerstone of management, with prophylaxis warranted in recurrent or severe cases. Early identification significantly reduces morbidity and mortality. Molecular diagnostic methods facilitate genotype-guided management, enabling precision medicine approaches in this context.</div></div><div><h3>Conclusion</h3><div>Timely recognition of MSMD, particularly in tuberculosis-endemic settings, is critical to prevent severe disease progression. A structured diagnostic algorithm, combined with molecular testing and individualized treatment strategies, enhances outcomes. MSMD underscores the significance of genotype-driven management.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"4 4","pages":"Article 100540"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145109612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab treatment and 3-dimensional bronchial tree changes in asthma-COPD overlap","authors":"Yoshiro Kai MD, PhD ,&nbsp;Yuichi Hishida RT","doi":"10.1016/j.jacig.2025.100530","DOIUrl":"10.1016/j.jacig.2025.100530","url":null,"abstract":"<div><div>Dupilumab treatment might be effective in improving lung function and exercise tolerance in patients with asthma–chronic obstructive pulmonary disease overlap. Three-dimensional bronchial tree visualization is a useful tool when assessing the functional response after treatment in these patients.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"4 4","pages":"Article 100530"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144662808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung function impairment and eosinophilia in patients with eosinophilic chronic rhinosinusitis","authors":"Yuki Sonoda MD ,&nbsp;Yoshimasa Imoto MD, PhD ,&nbsp;Ayako Maegawa MD ,&nbsp;Anna Shimizu MD ,&nbsp;Masanori Kidoguchi MD, PhD ,&nbsp;Rikako Gozawa MD ,&nbsp;Keisuke Koyama MD ,&nbsp;Naoto Adachi MD ,&nbsp;Taiyo Morikawa MD, PhD ,&nbsp;Yuto Miyazaki MD ,&nbsp;Takahiro Tokunaga MD, PhD ,&nbsp;Masafumi Sakashita MD, PhD ,&nbsp;Shigeharu Ueki MD, PhD ,&nbsp;Takechiyo Yamada MD, PhD ,&nbsp;Shigeharu Fujieda MD, PhD","doi":"10.1016/j.jacig.2025.100550","DOIUrl":"10.1016/j.jacig.2025.100550","url":null,"abstract":"<div><h3>Background</h3><div>Eosinophilic chronic rhinosinusitis (ECRS) is characterized by intense eosinophil infiltration in nasal polyps (NPs), related to asthma comorbidity and elevated circulating eosinophil levels. The mechanism by which these systemic components affect type 2 inflammation in NPs is poorly understood.</div></div><div><h3>Objective</h3><div>We sought to evaluate the relationship between lung function and eosinophilia in chronic rhinosinusitis and assess whether ECRS reflects lower airway involvement and systemic eosinophilic inflammation.</div></div><div><h3>Methods</h3><div>We examined 198 patients with chronic rhinosinusitis. Lung function was assessed preoperatively using spirometry and fractional exhaled nitric oxide (F<span>eno</span>). Patients were classified into ECRS and non-ECRS groups on the basis of the Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis score, and patients with odontogenic maxillary sinusitis (OMS) were included for comparison. mRNA expressions of inflammatory cytokines in NPs were measured by quantitative real-time PCR.</div></div><div><h3>Results</h3><div>FEV₁/forced vital capacity ratio, predicted FEV₁/forced vital capacity, and predicted maximum midexpiratory flow were significantly lower in the ECRS group than in the non-ECRS and OMS groups. F<span>eno</span> levels were significantly higher in the ECRS group. The Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis score correlated with lung function and F<span>eno</span>. Notably, some patients with ECRS showed impaired respiratory function and elevated F<span>eno</span> levels without a documented asthma diagnosis, suggesting possible undiagnosed asthma. Gene expression levels of type 2 cytokines in NPs were elevated in patients with ECRS and in those with peripheral eosinophilia greater than 5%.</div></div><div><h3>Conclusions</h3><div>Respiratory function was significantly lower in patients with ECRS without an asthma diagnosis compared with non-ECRS and OMS groups. Enhanced eosinophilic inflammation in NPs may affect the lower airways, suggesting an eosinophilic united airway disease.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"4 4","pages":"Article 100550"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144889975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Objective sensitization algorithm validates parental report of food allergy in children","authors":"Michael Gregor Sherenian MD ,&nbsp;Wan Chi Chang MS ,&nbsp;Cassandra Almasri BS ,&nbsp;Jocelyn M. Biagini PhD ,&nbsp;Alkis Togias MD ,&nbsp;Gurjit K. Khurana Hershey MD, PhD","doi":"10.1016/j.jacig.2025.100512","DOIUrl":"10.1016/j.jacig.2025.100512","url":null,"abstract":"<div><h3>Background</h3><div>The criterion standard to diagnose food allergy includes oral food challenge, which is expensive, carries some risk, and is often not feasible in large research cohort studies. Data regarding subjective food allergy screening tools such as parental report of physician-diagnosed food allergy have not been validated.</div></div><div><h3>Objective</h3><div>We sought to determine the level of agreement between parental report of physician-diagnosed food allergy and a food allergy algorithm diagnostic tool that uses objective sensitization markers in children.</div></div><div><h3>Methods</h3><div>We utilized longitudinal data that were collected from the Mechanisms of Progression of Atopic Dermatitis to Asthma in Children (MPAACH) early-life cohort over 4 annual visits to determine the association between parental report of food allergy and food allergy diagnosis using a food allergy algorithm based on a validated tool.</div></div><div><h3>Results</h3><div>Of a total of 671 participants, 563 were included in this study; 88 children were excluded because they did not have questionnaire and algorithm data for all 4 visits. A total of 6972 evaluations focusing on milk, egg, peanut, tree nuts, wheat, and soy were conducted. Compared with the food allergy algorithm, parental report of physician-diagnosed food allergy had a positive predictive value of 64.5% and a negative predictive value of 99.1%. The overall agreement did not differ substantially over time for the top 3 food allergens.</div></div><div><h3>Conclusion</h3><div>Parental report of physician-diagnosed food allergy can accurately determine children without food allergy; however, food allergy will likely be overestimated if a positive response is used to identify food allergy.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"4 4","pages":"Article 100512"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144722114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changing insect populations: New insects, old venoms","authors":"David B.K. Golden MDCM","doi":"10.1016/j.jacig.2025.100559","DOIUrl":"10.1016/j.jacig.2025.100559","url":null,"abstract":"","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"4 4","pages":"Article 100559"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144931822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mepolizumab for the management of chronic rhinosinusitis with nasal polyps across the United States: A retrospective study","authors":"Juan Carlos Cardet MD, MPH ,&nbsp;Jared Silver MD ,&nbsp;Martin Maldonado-Puebla MD ,&nbsp;François Laliberté MA ,&nbsp;Chi Gao PhD ,&nbsp;Ramya Ramasubramanian PhD ,&nbsp;Annalise Hilts BA ,&nbsp;Kaixin Zhang MSc ,&nbsp;Jeremiah Hwee PhD ,&nbsp;Waseem Ahmed MBA ,&nbsp;Amy G. Edgecomb PharmD, MPH","doi":"10.1016/j.jacig.2025.100549","DOIUrl":"10.1016/j.jacig.2025.100549","url":null,"abstract":"<div><h3>Background</h3><div>Retrospective data are limited on the effectiveness of mepolizumab treatment that is reflective of real-world practice in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).</div></div><div><h3>Objective</h3><div>We evaluated changes in administration of nasal polyp (NP)-related oral corticosteroids (OCS) and other treatments, exacerbations, sinus surgeries, NP-related health care resource utilization, and costs before and after mepolizumab initiation in patients with CRSwNP.</div></div><div><h3>Methods</h3><div>Retrospective cohort study using data from the Komodo Research database included adults with CRSwNP, without severe asthma, initiating mepolizumab therapy on or after July 29, 2021 (index date), with 12 months of continuous health care enrollment before index and ≥6 months after index. Treatment with reslizumab, benralizumab, or tezepelumab during the study period was excluded. Outcomes were compared pre- versus post-mepolizumab initiation for the overall population and on-label subgroup analysis.</div></div><div><h3>Results</h3><div>Mean number of NP-related OCS dispensings per patient per year (PPPY) (0.5 after vs 1.2 before therapy initiation), total mean OCS dose (119.1 vs 309.9 mg), mean daily OCS dose per period (0.3 vs 0.8 mg), and mean number of OCS bursts (0.3 vs 0.7) were significantly lower after versus before initiation, respectively (all <em>P</em> &lt; .001). Numbers of patients requiring NP-related treatments significantly decreased (75.0% post vs 86.7% pre, <em>P</em> &lt; .001). Mean number of NP-related exacerbations experienced by patients significantly reduced (1.6 PPPY pre vs 0.3 PPPY post). Mean number of sinus surgeries significantly reduced after initiation (annual rate ratio [95% confidence interval] 0.23 [0.13, 0.40], <em>P</em> &lt; .001), as did rate of otolaryngologist visits PPPY, excluding mepolizumab administration visits (rate ratio 0.52 [95% confidence interval 0.43, 0.63], <em>P</em> &lt; .001).</div></div><div><h3>Conclusion</h3><div>In this first retrospective mepolizumab study for patients with CRSwNP without severe asthma, improvements in all outcomes were observed after mepolizumab initiation.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"4 4","pages":"Article 100549"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144931836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}